
|Videos|April 24, 2023
ARVO LIVE: Trefoil Therapeutics CEO gives update on TTHX1114 in patients with FECD
Author(s)David Hutton, Martin David Harp
Ophthalmology Times® talked with David Eveleth, MD, CEO and Founder of Trefoil Therapeutics about TTHX1114 in patients with Fuchs endothelial corneal dystrophy (FECD) undergoing Descemet’s Stripping Only (DSO) in combination with cataract surgery at this year's ARVO meeting.
Advertisement
Ophthalmology Times® talked with David Eveleth, MD, CEO and Founder of Trefoil Therapeutics about TTHX1114 in patients with Fuchs endothelial corneal dystrophy (FECD) undergoing Descemet’s Stripping Only (DSO) in combination with cataract surgery at this year's ARVO meeting.
Video transcript
Editor’s note: Transcript lightly edited for clarity.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Ocugen publishes phase 1 GARDian1 gene therapy data for Stargardt disease
2
Rayner announces Sophi Phaco System in the US
3
FDA grants Fast Track Designation to Complement Therapeutics’ CTx001 for geographic atrophy
4
Ophthalmology pipeline watch: Key trial results and PDUFA dates for Q1 2026
5














































